PL4025592T3 - Sprzężone mimetyki hepcydyny do stosowania w leczeniu czerwienicy prawdziwej - Google Patents
Sprzężone mimetyki hepcydyny do stosowania w leczeniu czerwienicy prawdziwejInfo
- Publication number
- PL4025592T3 PL4025592T3 PL20860676.4T PL20860676T PL4025592T3 PL 4025592 T3 PL4025592 T3 PL 4025592T3 PL 20860676 T PL20860676 T PL 20860676T PL 4025592 T3 PL4025592 T3 PL 4025592T3
- Authority
- PL
- Poland
- Prior art keywords
- conjugated
- treatment
- polycythemia vera
- hepcidin mimetics
- hepcidin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962895201P | 2019-09-03 | 2019-09-03 | |
| US202062983515P | 2020-02-28 | 2020-02-28 | |
| US202063020945P | 2020-05-06 | 2020-05-06 | |
| US202063059747P | 2020-07-31 | 2020-07-31 | |
| PCT/US2020/049244 WO2021046246A1 (en) | 2019-09-03 | 2020-09-03 | Conjugated hepcidin mimetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4025592T3 true PL4025592T3 (pl) | 2026-03-16 |
Family
ID=74681239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20860676.4T PL4025592T3 (pl) | 2019-09-03 | 2020-09-03 | Sprzężone mimetyki hepcydyny do stosowania w leczeniu czerwienicy prawdziwej |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20220372099A1 (enExample) |
| EP (2) | EP4706671A3 (enExample) |
| JP (2) | JP7831841B2 (enExample) |
| KR (1) | KR20220075343A (enExample) |
| CN (1) | CN114729022A (enExample) |
| AU (2) | AU2020343328B2 (enExample) |
| BR (1) | BR112022003999A2 (enExample) |
| CA (1) | CA3152789A1 (enExample) |
| DK (1) | DK4025592T3 (enExample) |
| ES (1) | ES3058577T3 (enExample) |
| FI (1) | FI4025592T3 (enExample) |
| IL (1) | IL291030A (enExample) |
| MX (1) | MX2022002633A (enExample) |
| PH (1) | PH12022550510A1 (enExample) |
| PL (1) | PL4025592T3 (enExample) |
| WO (1) | WO2021046246A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| CA2949215C (en) | 2014-05-16 | 2023-03-14 | Protagonist Therapeutics, Inc. | .alpha.4.beta.7 integrin thioether peptide antagonists |
| SG10201810154WA (en) | 2014-07-17 | 2018-12-28 | Protagonist Therapeutics Inc | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| CA3009834A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| WO2018022937A1 (en) | 2016-07-27 | 2018-02-01 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases |
| WO2019157268A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| CA3104418A1 (en) | 2018-07-12 | 2020-01-16 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| MX2022008740A (es) | 2020-01-15 | 2022-09-23 | Janssen Biotech Inc | Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. |
| SMT202500254T1 (it) | 2020-01-15 | 2025-09-12 | Janssen Biotech Inc | Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie |
| AU2021383828A1 (en) | 2020-11-20 | 2023-07-06 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
| WO2022212696A1 (en) * | 2021-04-01 | 2022-10-06 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| CA3220871A1 (en) * | 2021-06-14 | 2022-12-22 | Protagonist Therapeutics, Inc. | Hepcidin mimetics for treatment of hereditary hemochromatosis |
| KR20240034224A (ko) | 2021-07-14 | 2024-03-13 | 얀센 바이오테크 인코포레이티드 | 인터류킨-23 수용체의 지질화된 펩티드 억제제 |
| US20250170216A1 (en) * | 2022-02-02 | 2025-05-29 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| EP4472995A4 (en) * | 2022-02-02 | 2025-11-19 | Protagonist Therapeutics Inc | Conjugated hepcidin mimetics |
| WO2024011188A1 (en) * | 2022-07-07 | 2024-01-11 | Protagonist Therapeutics, Inc. | Combination therapy for treatment of iron overload diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
| CA2361830A1 (en) | 1999-03-17 | 2000-09-21 | Novo Nordisk A/S | Method for acylating peptides and novel acylating agents |
| US7094785B1 (en) * | 2002-12-18 | 2006-08-22 | Cornell Research Foundation, Inc. | Method of treating polycythemia vera |
| NZ578948A (en) | 2007-02-15 | 2012-03-30 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists |
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| KR20170002414A (ko) * | 2014-04-07 | 2017-01-06 | 멀겐져 바이오텍, 아이엔씨. | 헵시딘 모방 펩티드 및 그 용도 |
| AU2015279571A1 (en) * | 2014-06-27 | 2017-02-02 | Protagonist Therapeutics, Inc. | Hepcidin and mini-hepcidin analogues and uses therof |
| WO2017068089A2 (en) | 2015-10-23 | 2017-04-27 | Vifor (International) Ag | Novel ferroportin inhibitors |
| CA3009834A1 (en) * | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| AU2017324446A1 (en) | 2016-09-06 | 2019-03-28 | La Jolla Pharmceutical Company | Methods of treating iron overload |
| WO2018128828A1 (en) | 2016-12-23 | 2018-07-12 | Bayer Healthcare Llc | Novel hepcidin mimetics and uses thereof |
| WO2019157268A1 (en) * | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
-
2020
- 2020-09-03 US US17/639,138 patent/US20220372099A1/en not_active Abandoned
- 2020-09-03 KR KR1020227011086A patent/KR20220075343A/ko active Pending
- 2020-09-03 CN CN202080076351.4A patent/CN114729022A/zh active Pending
- 2020-09-03 WO PCT/US2020/049244 patent/WO2021046246A1/en not_active Ceased
- 2020-09-03 CA CA3152789A patent/CA3152789A1/en active Pending
- 2020-09-03 AU AU2020343328A patent/AU2020343328B2/en active Active
- 2020-09-03 BR BR112022003999A patent/BR112022003999A2/pt unknown
- 2020-09-03 EP EP25211675.1A patent/EP4706671A3/en active Pending
- 2020-09-03 PH PH1/2022/550510A patent/PH12022550510A1/en unknown
- 2020-09-03 MX MX2022002633A patent/MX2022002633A/es unknown
- 2020-09-03 DK DK20860676.4T patent/DK4025592T3/da active
- 2020-09-03 JP JP2022540618A patent/JP7831841B2/ja active Active
- 2020-09-03 FI FIEP20860676.4T patent/FI4025592T3/fi active
- 2020-09-03 US US17/011,844 patent/US20210061872A1/en active Pending
- 2020-09-03 ES ES20860676T patent/ES3058577T3/es active Active
- 2020-09-03 EP EP20860676.4A patent/EP4025592B1/en active Active
- 2020-09-03 PL PL20860676.4T patent/PL4025592T3/pl unknown
-
2022
- 2022-03-01 IL IL291030A patent/IL291030A/en unknown
-
2025
- 2025-07-31 JP JP2025128508A patent/JP2025163134A/ja active Pending
-
2026
- 2026-06-29 AU AU2026205090A patent/AU2026205090A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7831841B2 (ja) | 2026-03-17 |
| AU2026205090A1 (en) | 2026-07-16 |
| FI4025592T3 (fi) | 2026-01-30 |
| US20220372099A1 (en) | 2022-11-24 |
| US20210061872A1 (en) | 2021-03-04 |
| JP2025163134A (ja) | 2025-10-28 |
| MX2022002633A (es) | 2022-06-02 |
| EP4706671A2 (en) | 2026-03-11 |
| AU2020343328A1 (en) | 2022-04-07 |
| EP4706671A3 (en) | 2026-04-01 |
| KR20220075343A (ko) | 2022-06-08 |
| PH12022550510A1 (en) | 2023-09-04 |
| JP2022546878A (ja) | 2022-11-09 |
| DK4025592T3 (da) | 2026-02-09 |
| ES3058577T3 (en) | 2026-03-11 |
| EP4025592A1 (en) | 2022-07-13 |
| EP4025592B1 (en) | 2025-10-29 |
| CN114729022A (zh) | 2022-07-08 |
| WO2021046246A1 (en) | 2021-03-11 |
| IL291030A (en) | 2022-05-01 |
| AU2020343328B2 (en) | 2026-04-09 |
| CA3152789A1 (en) | 2021-03-11 |
| BR112022003999A2 (pt) | 2022-05-31 |
| EP4025592A4 (en) | 2023-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4025592T3 (da) | Konjugerede hepcidinmimetika til behandling af polycythemia vera | |
| IL289975A (en) | Use of cannabidiol in the treatment of dravet syndrome | |
| IL282487A (en) | Tyk2 inhibitors and uses thereof | |
| HUE058931T2 (hu) | Pilokarpin hidroklorid alkalmazása presbyopia kezelésére | |
| EP3908270A4 (en) | COMBINATION OF DEXTROMETHORPHANE AND BUPROPION FOR THE TREATMENT OF DEPRESSION | |
| SI3661954T1 (sl) | Muteini interlevkina-21 in postopki zdravljenja | |
| SI3658557T1 (sl) | Zaviralci TYK2 in njihova uporaba | |
| IL276609A (en) | Combined treatment with epilimod and glutamatergic factors | |
| SI3716992T1 (sl) | Uporaba antagonistov VEGF za zdravljenje angiogenih očesnih motenj | |
| PL3889145T3 (pl) | 8-cyjano-5-piperydyno-chinoliny jako antagoniści TLR7/8 oraz ich zastosowanie w leczeniu zaburzeń immunologicznych | |
| PL3972643T3 (pl) | Antagoniści układu dopełniacza do stosowania w sposobach leczenia neuropatii paraproteinemicznych | |
| MX2019001669A (es) | Metodos y composiciones para el tratamiento de trastornos epilepticos. | |
| PL3806898T3 (pl) | Antagonista gremlin-1 do zastosowania w leczeniu nowotworu | |
| IL286248A (en) | Tyk2 inhibitors and uses thereof | |
| PL3325509T3 (pl) | Przeciwciała anty-TfR oraz ich zastosowanie w leczeniu zaburzeń proliferacyjnych i zapalnych | |
| HUE061761T2 (hu) | Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében | |
| PL3658140T3 (pl) | Połączenia aprocitentanu z dodatkowymi składnikami czynnymi do leczenia opornego nadciśnienia | |
| PT3481846T (pt) | 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda | |
| PL3768284T3 (pl) | Kompozycje z fageliny entrecoccus do zastosowania w terapii | |
| IL283511A (en) | Dendrimer for therapy and imaging | |
| GB201802307D0 (en) | CD36 antagonists for use in melanoma treatment | |
| IL287704A (en) | Use of cannabidiol in the treatment of tuberous sclerosis complex | |
| PT3773589T (pt) | Inibidor de ret para utilização no tratamento de cancro com alteração de ret | |
| PL3592355T3 (pl) | Kx2-391/kx-01 do zastosowania w leczeniu rogowacenia słonecznego | |
| PL3732294T3 (pl) | Tymohydrochinon do stosowania w leczeniu hiperglikemii |